Bruton’s tyrosine kinase (BTK) inhibitors have revolutionized the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). All three approved BTK inhibitors (ibrutinib, acalabrutinib, and zanubrutinib) have similar impressive efficacy, so treatment choices are often guided by which drug is safer and better tolerated. This study used a matching-adjusted indirect comparison (MAIC) method to compare data from different trials on acalabrutinib and zanubrutinib.
Dr. Brian Koffman reviews the study results presented at the American Society of Clinical Oncology (ASCO) 2023 annual meeting.
Read the full article on CLL Society's website at: cllsociety.org...
__________________________________________________________________________________________
CLL Society Website: cllsociety.org/
Facebook: / cllsociety
Twitter: / cllsociety
LinkedIn: / cll-society
16 ноя 2023
